Viracta Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript
I'm (inaudible) one of the biotech equity research analyst here at RBC Capital Markets, and we're pleased to have Viracta Therapeutics with us today. Joining us is Mark Rothera, President and CEO; and Dan Chevallard, COO and CFO. Thank you both for joining us.
Thank you.
Maybe just to get started for those who are not as familiar with Viracta, can you just provide us with a brief introduction of the company?
Sure. So Viracta was formed in 2015 and became a public company in 2021 and its mission is to bring to the world medicines for virus-associated cancers. And its lead program is called Nana-val. It's an all-oral combination of nanatinostat, which is a viral inducer, and valganciclovir, which kills EBV-associated cancer cells.
So within that mission, viral associated cancers, we are looking to address an important area of unmet need, which is
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
